On the Bright Side - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

On the Bright Side


Pharmaceutical Technology

Then the light came on


Control
Quality rejected the lot of injectable product because of a color change between the time of filling and the visual inspection, and I was told to find out what caused the color change. We had been making the product for 35 years and no one could remember such a problem before.

The visual inspection department supervisor told me that not all vials were affected, and that the effect seemed to be all related to one side of the pallet. So the path of that pallet of product was traced through the plant, where it was discovered it had been stored near a window for some weeks! It was a light-induced change. We immediately began a series of experiments to determine whether light could create the change, and it quickly became clear that sunlight or other strong lights such as sodium vapor lamps could cause the color change. One ingredient in the product was established as the causative agent in the color change.




The corrective action turned out to be quite simple: Don't put the product near a light source, and cover it with an opaque material before storage.

Dim ... but long lasting

Hey, he wasn't the brightest bulb in the box, but he was persistent. Back in the 1970s, the company evaluated medicinal drug product-release test results against statistical process control (SPC) limits. Although we'd never think of doing this today, at the time it was a common practice to reduce the shelf life of batches that had release test results outside the SPC limits but within the NDA-approved specifications.

So, in his duty as release officer, our dim bulb would notice the out-of-limits result and come to our stability group for a calculated shelf life. On this occasion, the lot was not only outside the SPC limits, but outside the NDA-approved specifications.

He wasn't too happy when we just laughed at him for even suggesting it had a shelf life. Try as we could, we never got him to understand that the lot had already expired as far as the government was concerned, even when we showed him the math (way beyond him, but hey, we tried), which gave a negative number for a shelf life! The batch never was released.

D stabilized

I had moved to a new company and was given responsibility for the stability program. An injectable multivitamin product showed signs of instability in vitamin D, so we reduced the expiration dating period for future batches. But the stability profile kept getting worse, and we realized that it would be hard to sell the product with a shelf life of less than 12 months.

An investigation team was set up, and during our shotgun investigation*, we noted that we had purchased the vitamin D in quantities sufficient for 50 finished product batches. For each batch, the bulk vitamin D was removed from the storage freezer, thawed, opened, and weighed in room-temperature and ambient-humidity weigh rooms. Analysis of the bulk confirmed that it was degrading despite the storage temperatures, apparently becaue of the numerous freeze–thaw cycles and the uptake of moisture during the thawing and opening.

Although a recall was never necessary, we did change the way the vitamin D raw material was weighed. The entire bulk lot into was divided into finished batch-sized quantities using glass vials that were deemed less likely to react immediately upon receipt and release. This division was performed in a glove box under dry conditions. The glass vials were then frozen and stored until needed for a batch, when only one at a time would be removed from the freezer and thawed for use.

*shotgun investigation: investigate a wide variety of possibilities at once, no matter how unlikely.

Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the secret files of Control, a senior compliance officer. If you have a story of clueless operators, oblivious management, inopportune lapses of judgment, or Murphy's Law in action, please send it to Control at
. We won't use any names, but if we do use your tale of disaster, courage, or just plain weirdness, Control will send you a coveted Pharmaceutical Technology t-shirt.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here